Bernadette Pöllinger1, Wolfgang Schmidt1, Anna Seiffert2, Heidi Imhoff1, Martin Emmert3. 1. Market Access, MSD Sharp & Dohme GmbH, Haar, Germany. 2. Gesundheitsforen Leipzig GmbH, Leipzig, Germany. 3. Versorgungsmanagement an der Friedrich-Alexander-Universität Erlangen-Nürnberg, Raum 5.255, Lange Gasse 20, 90403, Nuremberg, Germany. martin.emmert@fau.de.
Abstract
AIMS: We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation. METHODS: The retrospective cohort study analysed the de-identified prescription data of the Arvato Health Analytics (Munich, Germany) database (2010-2015) in adult UC patients undergoing adalimumab therapy. RESULTS: A total of 154 patients were newly treated with adalimumab (average 39.6 years, 53% females), with a mean dose of 2.93 mg/day. Within 12 months, 69 patients (45%) received a dose increase of > 50% (doubled dose in 48 patients; 32%), with the escalation reported at 169.3 ± 99.3 days. A subsequent dose de-escalation to the standard dose occurred in 50 (32%) of patients that initially had a dose increase of > 50% (after 94.7 ± 49.6 days). Direct drug costs were 28,846 € in the overall study population, 24,934 € in patients on standard dose, 36,094 € in patients with dose increase, and 32,742 € in patients with increase and subsequent decrease. CONCLUSION: Dose escalation occurred frequently, and in one third of patients the dose was at least doubled. Dose escalations were associated with substantial increases in direct drug costs. Dose escalation of adalimumab can severely affect both the health care system and the drug budget of the physician. It needs to be considered that other biologic medications may constitute a more cost-effective alternative.
AIMS: We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation. METHODS: The retrospective cohort study analysed the de-identified prescription data of the Arvato Health Analytics (Munich, Germany) database (2010-2015) in adult UC patients undergoing adalimumab therapy. RESULTS: A total of 154 patients were newly treated with adalimumab (average 39.6 years, 53% females), with a mean dose of 2.93 mg/day. Within 12 months, 69 patients (45%) received a dose increase of > 50% (doubled dose in 48 patients; 32%), with the escalation reported at 169.3 ± 99.3 days. A subsequent dose de-escalation to the standard dose occurred in 50 (32%) of patients that initially had a dose increase of > 50% (after 94.7 ± 49.6 days). Direct drug costs were 28,846 € in the overall study population, 24,934 € in patients on standard dose, 36,094 € in patients with dose increase, and 32,742 € in patients with increase and subsequent decrease. CONCLUSION: Dose escalation occurred frequently, and in one third of patients the dose was at least doubled. Dose escalations were associated with substantial increases in direct drug costs. Dose escalation of adalimumab can severely affect both the health care system and the drug budget of the physician. It needs to be considered that other biologic medications may constitute a more cost-effective alternative.
Entities:
Keywords:
Adalimumab; Direct drug costs; Drug utilisation; Economic analysis; Observational; Ulcerative colitis
Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: Waqqas Afif; Jonathan A Leighton; Stephen B Hanauer; Edward V Loftus; William A Faubion; Darrell S Pardi; William J Tremaine; Sunanda V Kane; David H Bruining; Russell D Cohen; David T Rubin; Karen A Hanson; William J Sandborn Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: A Oussalah; C Laclotte; J-B Chevaux; M Bensenane; A Babouri; A-A Serre; T Boucekkine; X Roblin; M-A Bigard; L Peyrin-Biroulet Journal: Aliment Pharmacol Ther Date: 2008-07-24 Impact factor: 8.171
Authors: Jean-Frederic Colombel; William J Sandborn; Subrata Ghosh; Douglas C Wolf; Remo Panaccione; Brian Feagan; Walter Reinisch; Anne M Robinson; Andreas Lazar; Martina Kron; Bidan Huang; Martha Skup; Roopal B Thakkar Journal: Am J Gastroenterol Date: 2014-08-26 Impact factor: 10.864
Authors: Pepijn W A Thomas; Lisa J T Smits; Maarten Te Groen; Rachel L West; Maurice G V M Russel; Jeroen M Jansen; Tessa E H Römkens; Frank Hoentjen Journal: Eur J Gastroenterol Hepatol Date: 2022-05-01 Impact factor: 2.586